Literature DB >> 25126270

Partial compliance with antipsychotics increases mental health hospitalizations in schizophrenic patients: analysis of a national managed care database.

Chris M Kozma1, Peter J Weiden2.   

Abstract

OBJECTIVE: To investigate the relationship between partial compliance with antipsychotic medication and mental health hospitalization in managed care patients with schizophrenia. STUDY
DESIGN: We performed a retrospective evaluation of 1499 outpatients with ≥1 antipsychotic claims and a diagnosis of schizophrenia in a managed care database (PHARMetrics).
METHODS: Patients were followed for 12 months after their initial oral antipsychotic prescribing event. Compliance was estimated by gaps in medication therapy, medication consistency and persistence, and medication possession ratio. Categorical and logistic regression analyses modeled effects of compliance, age, and gender on hospitalization risk.
RESULTS: The managed care cohort had an overall hospitalization risk of 5.9% during follow-up. Increased hospitalization risk was associated with lower partial compliance, as measured by 3 of the 4 definitions. Patients with a maximum gap of >30 days were 4.7 times more likely to be hospitalized than those with a maximum gap of 0 to 10 days (P <.001). Low medication consistency of <70% and a medication possession ratio of <70% were significantly associated with increased risk of hospitalization (P <.001). Logistic regression analyses indicated that hospitalization odds decreased 16.9% (P <.001) and 18.8% (P <.001) for every 10% increase in medication possession ratio and medication consistency, respectively.
CONCLUSION: Small decreases in compliance with antipsychotics are associated with increased hospitalization risk among patients with schizophrenia in a managed care population.

Entities:  

Year:  2009        PMID: 25126270      PMCID: PMC4106590     

Source DB:  PubMed          Journal:  Am Health Drug Benefits        ISSN: 1942-2962


  24 in total

1.  Psychopharmacology: Perspectives on medication adherence and atypical antipsychotic medications.

Authors:  Dawn I Velligan; Francis Lam; Larry Ereshefsky; Alexander L Miller
Journal:  Psychiatr Serv       Date:  2003-05       Impact factor: 3.084

2.  Adherence to treatment with antipsychotic medication and health care costs among Medicaid beneficiaries with schizophrenia.

Authors:  Todd P Gilmer; Christian R Dolder; Jonathan P Lacro; David P Folsom; Laurie Lindamer; Piedad Garcia; Dilip V Jeste
Journal:  Am J Psychiatry       Date:  2004-04       Impact factor: 18.112

Review 3.  The assessment of refill compliance using pharmacy records: methods, validity, and applications.

Authors:  J F Steiner; A V Prochazka
Journal:  J Clin Epidemiol       Date:  1997-01       Impact factor: 6.437

4.  The economic burden of schizophrenia in the United States in 2002.

Authors:  Eric Q Wu; Howard G Birnbaum; Lizheng Shi; Daniel E Ball; Ronald C Kessler; Matthew Moulis; Jyoti Aggarwal
Journal:  J Clin Psychiatry       Date:  2005-09       Impact factor: 4.384

5.  Use patterns for antipsychotic medications in medicaid patients with schizophrenia.

Authors:  J S McCombs; M B Nichol; G L Stimmel; J Shi; R R Smith
Journal:  J Clin Psychiatry       Date:  1999       Impact factor: 4.384

6.  Copayment level and compliance with antihypertensive medication: analysis and policy implications for managed care.

Authors:  Deborah A Taira; Ken S Wong; Feride Frech-Tamas; Richard S Chung
Journal:  Am J Manag Care       Date:  2006-11       Impact factor: 2.229

7.  Effect of value-added utilities on prescription refill compliance and Medicaid health care expenditures--a study of patients with non-insulin-dependent diabetes mellitus.

Authors:  T L Skaer; D A Sclar; D J Markowski; J K Won
Journal:  J Clin Pharm Ther       Date:  1993-08       Impact factor: 2.512

8.  Pharmacy benefits and the use of drugs by the chronically ill.

Authors:  Dana P Goldman; Geoffrey F Joyce; Jose J Escarce; Jennifer E Pace; Matthew D Solomon; Marianne Laouri; Pamela B Landsman; Steven M Teutsch
Journal:  JAMA       Date:  2004-05-19       Impact factor: 56.272

9.  Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission.

Authors:  Marcia Valenstein; Laurel A Copeland; Frederic C Blow; John F McCarthy; John E Zeber; Leah Gillon; C Raymond Bingham; Thomas Stavenger
Journal:  Med Care       Date:  2002-08       Impact factor: 2.983

10.  A general method of compliance assessment using centralized pharmacy records. Description and validation.

Authors:  J F Steiner; T D Koepsell; S D Fihn; T S Inui
Journal:  Med Care       Date:  1988-08       Impact factor: 2.983

View more
  12 in total

1.  Heterogeneity of Treatment Effects of Long-Acting Injectable Antipsychotic Medications.

Authors:  T Scott Stroup; Natalie A Bareis; Robert A Rosenheck; Marvin S Swartz; Joseph P McEvoy
Journal:  J Clin Psychiatry       Date:  2018-11-27       Impact factor: 4.384

2.  Factors Associated with Adherence to the HEDIS Quality Measure in Medicaid Patients with Schizophrenia.

Authors:  Marie-Hélène Lafeuille; Christian Frois; Michel Cloutier; Mei Sheng Duh; Patrick Lefebvre; Jacqueline Pesa; Zoe Clancy; John Fastenau; Mike Durkin
Journal:  Am Health Drug Benefits       Date:  2016-10

3.  Comparative Effectiveness of Adjunctive Psychotropic Medications in Patients With Schizophrenia.

Authors:  T Scott Stroup; Tobias Gerhard; Stephen Crystal; Cecilia Huang; Zhiqiang Tan; Melanie M Wall; Chacku Mathai; Mark Olfson
Journal:  JAMA Psychiatry       Date:  2019-05-01       Impact factor: 21.596

4.  Comparative Safety Signal Assessment of Hospitalization Associated With the Use of Atypical Antipsychotics.

Authors:  Ismaeel Yunusa; Chengwen Teng; Ibraheem M Karaye; Emily Crounse; Saud Alsahali; Nasim Maleki
Journal:  Front Psychiatry       Date:  2022-06-06       Impact factor: 5.435

5.  Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review.

Authors:  Kyoko Higashi; Goran Medic; Kavi J Littlewood; Teresa Diez; Ola Granström; Marc De Hert
Journal:  Ther Adv Psychopharmacol       Date:  2013-08

6.  Factors associated with medication adherence among patients with schizophrenia in Mekelle, Northern Ethiopia.

Authors:  Tadele Eticha; Amha Teklu; Dagim Ali; Gebremedhin Solomon; Adissu Alemayehu
Journal:  PLoS One       Date:  2015-03-27       Impact factor: 3.240

7.  Adherence and rehospitalizations in patients with schizophrenia: evidence from Japanese claims data.

Authors:  Hiroyo Kuwabara; Yoshimichi Saito; Jörg Mahlich
Journal:  Neuropsychiatr Dis Treat       Date:  2015-04-01       Impact factor: 2.570

8.  Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.

Authors:  Andreas Schreiner; Asaf Caspi; Paul Bergmans; Pierre Cherubin; Sofia Keim; Elsa Lara; Irina Pinchuk; Daniel Schuepbach; Sajid Suleman; Ludger Hargarter
Journal:  Psychopharmacology (Berl)       Date:  2016-11-05       Impact factor: 4.530

9.  Drug Utilization of Japanese Patients Diagnosed with Schizophrenia: An Administrative Database Analysis.

Authors:  Stephane Cheung; Yukinobu Hamuro; Jörg Mahlich; Takanobu Nakahara; Rosarin Sruamsiri; Sunny Tsukazawa
Journal:  Clin Drug Investig       Date:  2017-06       Impact factor: 2.859

10.  Hospitalization and cost after switching from atypical to typical antipsychotics in schizophrenia patients in Thailand.

Authors:  Tuanthon Boonlue; Suphat Subongkot; Piyameth Dilokthornsakul; Ronnachai Kongsakon; Oraluck Pattanaprateep; Orabhorn Suanchang; Nathorn Chaiyakunapruk
Journal:  Clinicoecon Outcomes Res       Date:  2016-04-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.